Bibliography
- Charo IF, Myers SJ, Herman A, Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994;91:2752-6
- Murphy PM, Baggiolini M, Charo IF, International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;21:145-76
- Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000;12:511-16
- Szekanecz Z, Szucs G, Szanto S, Koch AE. Chemokines in rheumatic diseases. Curr Drug Targets 2006;7:91-102
- Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21
- Taylor PC, Peters AM, Paleolog E, Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47
- Min DJ, Cho ML, Lee SH, Augmented production of chemokines by the interaction of type II collagen-reactive T cells with rheumatoid synovial fibroblasts. Arthritis Rheum 2004;50:1146-55
- Katschke KJ Jr, Rottman JB, Ruth JH, Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44:1022-32
- Ellingsen T, Hornung N, Moller BK, Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann Rheum Dis 2007;66:151-7
- Haringman JJ, Gerlag DM, Smeets TJ, A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2387-92
- Vergunst CE, Gerlag DM, Lopatinskaya L, Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9
- Braddock M. Advances in anti-inflammatory therapeutics: London, UK. Expert Opin Investig Drugs 2007;16:257-61
- Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997;62:681-7
- Gosling J, Slaymaker S, Gu L, MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-8
- Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7
- Van Lomen G, Doyon J, Coesemans E, 2-Mercaptoimidazoles, a new class of potent CCR2 antagonists. Bioorg Med Chem Lett 2005;15:497-500
- Lagu B, Gerchak C, Pan M, Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. Bioorg Med Chem Lett 2007;17:4382-6
- Xia M, Hou C, Demong D, Substituted dipiperidine alcohols as potent CCR2 antagonists. Bioorg Med Chem Lett 2008;18:3562-4
- Xia M, Hou C, DeMong DE, Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. J Med Chem 2007;50:5561-3
- Xia M, Hou C, Pollack S, Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists. Bioorg Med Chem Lett 2007;17:5964-8
- Zhang X, Hufnagel HR, Sui Z. 4-AZETIDINYL-I-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2. In US 2010/0267668. 2010
- Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8
- Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15
- Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
- Doranz BJ, Rucker J, Yi YJ, A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58
- Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 2009;19:39-58
- Pease JE, Horuk R. Chemokine receptor antagonists:Part 2. Expert Opin Ther Pat 2009;19:199-221
- MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008;47:236-41
- DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009;8:105-6
- Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009;8:23-33